Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.56 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.56 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.50 |
| ▸ | HTR7 | P34969 | 3/20 | 0.49 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | MMP3 | P08254 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24069065 | 0.93 | HTR7 (0.56) | KDM1AOPRM1OPRK1CARM1PRMT6 | |
| SCHEMBL25758471 | 0.84 | HTR7 (0.60) | KDM1ACARM1PRMT6SMN1; SMN2HTR7 | |
| SCHEMBL25758458 | 0.83 | SLC6A2 (0.61) | KDM1ACARM1PRMT6KDM4ELMNA | |
| SCHEMBL29022591 | 0.80 | HTR1A (0.67) | KDM4ELMNAGAAMAPTSMN1; SMN2 | |
| SCHEMBL25758490 | 0.80 | HTR7 (0.72) | KDM4ELMNAGAAMAPTSMN1; SMN2 | |
| SCHEMBL26213077 | 0.78 | KDM1A (0.47) | KDM1AOPRM1OPRK1KDM4ELMNA | |
| SCHEMBL24070221 | 0.78 | HTR7 (0.61) | CARM1PRMT6HTR7DRD2 | |
| SCHEMBL25758563 | 0.78 | HTR7 (0.69) | HTR7DRD2 | |
| SCHEMBL19048139 | 0.78 | KDM1A (0.61) | KDM1AKDM4ELMNASMN1; SMN2SIGMAR1 | |
| SCHEMBL3886047 | 0.78 | KDM1A (0.61) | KDM1AKDM4ELMNASMN1; SMN2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116157124-A | Sulfonamide derivative and pharmaceutical composition for preventing or treating mental diseases containing the same as active ingredient | 大邱庆北尖端医疗产业振兴财团 | 2023-05-23 | — | — | CN | claimed |
| US-20230212121-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | TRINEURO (KR) | 2023-07-06 | — | — | US | disclosed |
| US-20230212121-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | TRINEURO (KR) | 2023-07-06 | — | — | US | disclosed |
| CN-116157124-A | Sulfonamide derivative and pharmaceutical composition for preventing or treating mental diseases containing the same as active ingredient | 大邱庆北尖端医疗产业振兴财团 | 2023-05-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212121-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | SLC6A2, SLC6A3, SLC6A4 | KDM1A 1266/4885OPRM1 935/4885OPRK1 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.